Intraosseous access is the first practical alternative for delayed peripheral or central intravenous access in emergencies that involves the vascular device with the end of the intraosseous catheter placed into the bone matrix, and thus, making it a route for primary means of vascular access in critically injured patients. Medications are introduced in the human bone marrow by using intraosseous infusion to provide an entry point in systemic circulation. The devices used for these are called intraosseous infusion devices. Thus, the introduction of such advanced products in the market is expected to drive growth of the global intraosseous infusion devices market over the forecast period.
The key players in the medical devices industry are focusing on the development of technologically advanced equipment, instruments, and systems for various surgical procedures. Thus, introduction of such advanced products in the market is expected to drive growth of the global intraosseous infusion devices market over the forecast period. For instance, in June 2020, Resuscitation Committee approved emergency intraosseous (IO) cannulation for in-patients across Cardiff and Vale University Health Board. It will harmonise the education and clinical delivery of IO access. IO access has been included in recent Resuscitation Council U.K. (2010) adult Advanced Life Support (ALS) guidelines for cases in which intravenous access is difficult or unavailable.
- This report provides an in-depth analysis of the global intraosseous infusion devices market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global intraosseous infusion devices market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include PerSys Medical, Aero Healthcare AU Pty Ltd, Teleflex Incorporated, PAVmed Inc., BIOPSYBELL S.R.L., Becton Dickinson Company, Cook Group, SAM Medical, Argon Medical Devices, Inc., Cardinal Health, Inc., StarFish Product Engineering Inc., and Medax SRL unipersonle.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global intraosseous infusion devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global intraosseous infusion devices market
- FAST 1 Device
- FAST x Device
- Bone Injection Gun (BIG) Devices
- EZ-IO Device
- NIO Device
- Dieckmann Modified Needle
- Jamshidi Needle
-
- Manual IO Needles
- Battery Powered Driver
- Impact Driven Devices
-
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others (Pre-hospital Emergency Care, Military Hospitals, etc.)
-
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
-
- PerSys Medical
- Aero Healthcare AU Pty Ltd
- Teleflex Incorporated
- PAVmed Inc.
- Becton Dickinson Company
- BIOPSYBELL S.R.L.
- Cook Group
- SAM Medical
- Argon Medical Devices, Inc.
- Cardinal Health, Inc.
- StarFish Product Engineering Inc.
- Medax SRL unipersonle
